Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.

In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.

Please note that ABCD reserve the right to amend the programme.

Workshops

Delegates will rotate around all the workshops:

Workshop A - Diabetic emergencies, Professor Ketan Dhatariya & Dr Omar Mustafa

Workshop B - Foot disease in diabetes, Professor Fran Game & Dr Catherine Gooday

Workshop C - Cardiovascular disease and diabetes, Dr Faizanur Rahman & Dr David Webb

Workshop D - Mental health and diabetes, Dr Hermione Price & Dr Marietta Stadler

This course has been instigated and organised by ABCD. Sponsors have contributed funding towards this event in return for exhibition space. They have had no input into the agenda or the selection of speakers with the exception of any sponsored symposia which are clearly indicated.

At the recent 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois, there were three presentations from the ABCD audit programme.

Insights From The Association Of British Clinical Diabetologists

K. Su Khin^1,2, T. Crabtree^1,2, A. L. Liarakos^1,2, V. Oguntolu³, A. Gough³, G. R. Mudiyanselage³, K. A. Adamson⁴, E. G. Wilmot^1,2, I. Idris ^1,2, R. E. J. Ryder⁵

REJ RYDER¹, A ESCALONA², R LOPEZ-GONZALEZ³, C LAZZARA³, J PUJOL-GEBELLI³, J STEIN⁴, T BATTELINO⁵, JP TEARE⁶, A RUBAN⁶, M HALUZIK⁷, L MUNRO⁸, H FRYDENBERG⁸, JJ.